Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
GlaxoSmithKline Pharmaceuticals Q2 net profit rises 16% to Rs 252 crore
Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...
money.rediff11d
GlaxoSmithKline Q2 Profit Rises 16% to Rs 252 cr
GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.
University of Delaware26d
Beyond preventing shingles
funded by GlaxoSmithKline (GSK), which makes Shingrix, will allow Harris to emulate two target trials using observational data. He’ll examine Shingrix's real-world effectiveness in preventing HZ ...
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...
Yahoo Finance3d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...
Taiwan News11d
AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
HONG KONG SAR - Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30 th October that mRNA respiratory syncytial virus (RSV) vaccine developed by a ...
Curevo Presents Positive Shingles Vaccine Outcomes Data
Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...
GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
GlaxoSmithKline Pharma Q2 results: Net profit rises 16% to Rs 252 cr
GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...
Yahoo Finance9d
Curevo Presents Positive Shingles Vaccine Outcomes Data
SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with ...